1.

Indirect medical costs (travel costs).

1.

Total reported units of healthcare utilization and total reported days of absenteeism and presenteeism in the ACT-group and CBT-group at over assessments.

1.

Mean and median incremental costs and effects of the 2,500 bootstraps.

1.

CONSORT 2010 checklist of information to include when reporting a randomised trial.

1.

Cost-effectiveness planes of the sensitivity analyses.

1.

Flowchart of study participants.

1.

Cost-effectiveness plane reflecting the probability that blended ACT is cost-effective compared to CBT in terms of treatment responders.

1.

Cost-effectiveness plane reflecting the probability that blended ACT is cost-effective compared to CBT in terms of QALYs (cost-utility).

1.

Acceptability curve reflecting the probability that blended ACT is cost-effective compared to CBT in terms of QALYs (cost-utility) at different willingness-to-pay ceilings.

1.

Baseline characteristics of study sample.